Navigation Links
Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Date:4/17/2008

Tepha Corporate Partners, Aesculap and Tornier, Conduct Clinical

Evaluations of TephaFLEX(R) Suture Products

LEXINGTON, Mass., April 17 /PRNewswire/ -- Tepha, Inc., a developer of medical devices derived from a new class of polymers, announced today that two of its corporate partners, Aesculap and Tornier, are conducting initial clinical evaluations of the Company's new TephaFLEX(R) suture products. These clinical evaluations, conducted in both the United States and Europe, represent the first human usage of medical devices derived from Tepha's new class of resorbable polymers called polyhydroxyalkanoates ("PHA's"). The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. TephaFLEX(R) monofilament suture is up to 30% stronger, more flexible, and has longer strength retention than currently marketed resorbable sutures.

Dr. Simon Williams, President and CEO of Tepha, commented, "The first human usage of a medical device based on our proprietary polymer technology is an important milestone in Tepha's history. We are grateful for the support of such capable and committed partners as Aesculap and Tornier, and we look forward to these collaborations progressing to the successful commercialization of TephaFLEX(R) suture products."

Aesculap AG, a Tepha corporate partner since 2004, currently is conducting a European trial evaluating suture products based on TephaFLEX(R) fiber in 150 patients undergoing abdominal wall repair procedures. The results of this trial will be submitted to European regulatory authorities to support Aesculap's application for CE Mark approval. Based in Germany, Aesculap is a division of B. Braun Melsungen AG, focused on products for core processes in operative medicine. Aesculap's product range includes sutures, implants for orthopedic and spinal surgery, surgical instruments, endoscopes, surgical motor systems, container and storage systems, and vascular therapy products.

Tornier, a Tepha corporate partner since 2007, recently supported the clinical evaluation of the TephaFLEX(R) Absorbable Suture by several leading orthopedic surgeons in the United States. The TephaFLEX(R) Absorbable Suture, FDA 510(k) cleared in February 2007, was utilized in a range of orthopedic soft tissue repair procedures. Tornier, based in Edina, Minnesota, is a leader in the extremity orthopedics market and is collaborating with Tepha on several products for orthopedic soft tissue repair.

About Tepha, Inc.

Tepha, Inc, is a developer of medical devices derived from a new class of resorbable polymers that have been engineered utilizing recombinant DNA technology. The unique biologic and mechanical properties of the Tepha PHA polymers has been recognized by an expanding list of corporate partners that now includes Aesculap AG, ENTrigue Surgical, HemCon Medical Technologies, LifeCell Corporation (Nasdaq: LIFC), NMT Medical (Nasdaq: NMTI), and Tornier, Inc. Tepha received its first FDA 510(k) clearance for its TephaFLEX(R) Absorbable Suture in February, 2007 and the Company and its partners have now received five 510(k)'s covering a range of medical devices including sutures, meshes, and films.

For further information about Tepha, please contact Dr. Ajay Ahuja, M.D., Director of Business Development, Tepha, Inc., 99 Hayden Ave, Lexington, MA 02421, tel: 781-357-1700. Email: contact@tepha.com. Or visit: http://www.tepha.com


'/>"/>
SOURCE Tepha, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
(Date:2/23/2017)... Persistence Market Research has ... for intraoperative imaging, excerpts from which predict the ... million. According to the report, the demand for ... of increasing adoption of minimally-invasive surgeries and remarkable ... for neurosurgeries. The world,s leading medical research institutes ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 9.2% over the next decade ... report analyzes the market estimates and forecasts for all the given ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing quality ... conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. ... Mason Health System in Seattle since 2000. In addition to his role at Virginia ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Curemark, LLC ... safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling ... sites already enrolling children across the United States. , “There are currently no ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don ... disciplined exercise regime, the author was able to successfully recover. In “ Origin & ... information for various sources on the principals of massage, anatomy , trigger ...
Breaking Medicine News(10 mins):